Robert Schmidt is the Corporate Controller and Chief Accounting Officer at ADC Therapeutics.
Mr. Schmidt joined ADC Therapeutics from Newell Brands, where he most recently served as Chief Accounting Officer. While at Newell Brands, Mr. Schmidt was responsible for all aspects of accounting and financial reporting as well as ensuring the compliance with accounting standards and rules and regulations of the U.S. Securities and Exchange Commission. Prior to Newell Brands, Mr. Schmidt served as the Assistant Corporate Controller of Celgene Corporation before the company’s acquisition by Bristol-Myers Squibb Company. Earlier in his career, Mr. Schmidt held various accounting positions of increasing responsibility at Tyco International plc, joining the company as Director of External Reporting to serving as the Corporate Controller prior to the company’s acquisition by Johnson Controls, Inc.
Mr. Schmidt started his career within the assurance practice of PricewaterhouseCoopers LLP including an assignment in the firm’s National Office Practice.
Mr. Schmidt earned his Bachelor of Arts in Accounting and Economics from Muhlenberg College.